110 related articles for article (PubMed ID: 24611663)
1. Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.
Goy A; Berger M; Ford P; Feldman T; Mato A; Bejot C; Fung HC
Leuk Lymphoma; 2014 Dec; 55(12):2932-4. PubMed ID: 24611663
[No Abstract] [Full Text] [Related]
2. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF; Montalbán C; De Sevilla AF; Martínez-López J; Díaz N; Canales M; Martínez R; Sánchez-Godoy P; Caballero MD; Peñalver J; Prieto E; Salar A; Burgaleta C; Queizán JA; Bajo R; De Oña R; De La Serna J
Leuk Lymphoma; 2011 Mar; 52(3):409-16. PubMed ID: 21275633
[TBL] [Abstract][Full Text] [Related]
3. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
4. Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?
Tam CS; Seymour JF
Leuk Lymphoma; 2011 May; 52(5):729-31. PubMed ID: 21504295
[No Abstract] [Full Text] [Related]
5. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
[TBL] [Abstract][Full Text] [Related]
8. [Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma].
Alonso JJ; Cánovas A; Rubio G
Med Clin (Barc); 2013 Nov; 141(10):459-60. PubMed ID: 23622890
[No Abstract] [Full Text] [Related]
9. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.
Jacobs SA; Swerdlow SH; Kant J; Foon KA; Jankowitz R; Land SR; DeMonaco N; Joyce J; Osborn JL; Evans TL; Schaefer PM; Luong TM
Clin Cancer Res; 2008 Nov; 14(21):7088-94. PubMed ID: 18981007
[TBL] [Abstract][Full Text] [Related]
11. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.
Croxtall JD
Drugs; 2011 May; 71(7):885-95. PubMed ID: 21568365
[TBL] [Abstract][Full Text] [Related]
13. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
Liapis K; Harhalakis N; Stefanou G; Apostolidis J
J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
[No Abstract] [Full Text] [Related]
14. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
15. Early initial therapy of advanced follicular lymphoma: the need for vigilance.
Sweetenham JW; Freedman AS
Leuk Lymphoma; 2011 Mar; 52(3):355-7. PubMed ID: 21323517
[No Abstract] [Full Text] [Related]
16. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
18. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
[TBL] [Abstract][Full Text] [Related]
19. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-induced serum sickness in a patient with follicular lymphoma.
Disperati P; Hicks LK; Buckstein R
Leuk Lymphoma; 2007 Aug; 48(8):1633-5. PubMed ID: 17701597
[No Abstract] [Full Text] [Related]
[Next] [New Search]